Skip to content
TrialScanner

NCT03815396

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency

Phase 1CompletedINBXLead

Registry record

Lead sponsor
Inhibrx Biosciences, Inc
Conditions
Alpha-1 Antitrypsin Deficiency; AATD
Primary completion
Aug 18, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03815396 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03815396: Phase 1 Study to Assess the... | TrialScanner